NGNE vs. ADPT, GYRE, MRVI, ELVN, PAHC, COLL, COGT, NTLA, ZYME, and PHVS
Should you be buying Neurogene stock or one of its competitors? The main competitors of Neurogene include Adaptive Biotechnologies (ADPT), Gyre Therapeutics (GYRE), Maravai LifeSciences (MRVI), Enliven Therapeutics (ELVN), Phibro Animal Health (PAHC), Collegium Pharmaceutical (COLL), Cogent Biosciences (COGT), Intellia Therapeutics (NTLA), Zymeworks (ZYME), and Pharvaris (PHVS). These companies are all part of the "pharmaceutical products" industry.
Neurogene vs.
Neurogene (NASDAQ:NGNE) and Adaptive Biotechnologies (NASDAQ:ADPT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends, community ranking and institutional ownership.
Neurogene has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -89.12%. Neurogene's return on equity of -32.81% beat Adaptive Biotechnologies' return on equity.
52.4% of Neurogene shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 9.9% of Neurogene shares are held by company insiders. Comparatively, 6.2% of Adaptive Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Neurogene has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500.
Neurogene has higher earnings, but lower revenue than Adaptive Biotechnologies.
Neurogene presently has a consensus target price of $60.83, suggesting a potential upside of 250.42%. Adaptive Biotechnologies has a consensus target price of $9.10, suggesting a potential upside of 10.04%. Given Neurogene's stronger consensus rating and higher probable upside, equities analysts clearly believe Neurogene is more favorable than Adaptive Biotechnologies.
Adaptive Biotechnologies received 71 more outperform votes than Neurogene when rated by MarketBeat users. However, 100.00% of users gave Neurogene an outperform vote while only 57.74% of users gave Adaptive Biotechnologies an outperform vote.
In the previous week, Adaptive Biotechnologies had 9 more articles in the media than Neurogene. MarketBeat recorded 11 mentions for Adaptive Biotechnologies and 2 mentions for Neurogene. Adaptive Biotechnologies' average media sentiment score of 0.34 beat Neurogene's score of 0.23 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.
Summary
Neurogene beats Adaptive Biotechnologies on 9 of the 16 factors compared between the two stocks.
Get Neurogene News Delivered to You Automatically
Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neurogene Competitors List
Related Companies and Tools
This page (NASDAQ:NGNE) was last updated on 2/22/2025 by MarketBeat.com Staff
